Patent GB-1190403-A (GB)
Title: 4-Hydroxy-2-Butenoic Acid Lactones
IPC: A61K31/58
Filed: 1967-05-22
Abstract: 1,190,403. Steroid-17-lactones and -17- furans. AYERST, McKENNA & HARRISON Ltd. 22 May, 1967 [24 May, 1966; 10 April, 1967], No. 23687/67. Heading C2U. Novel steroids of formula wherein St is a steroid radical of the estrane or androstane series connected by the 17- position thereof to the lactone ring and X is H, Cl or Br are prepared by reacting 17-furylsteroids of formula with hypobromous or hypochlorous acid or a reagent capable of furnishing the elements thereof, any labile primary or secondary hydroxyl groups or isolated double bonds present in the radical St having previously been protected. The reaction product generally comprises a mixture of products of Formula I wherein X is H and Cl or Br which may be separated by chloromatography or crystallization. The product mixture is alternatively treated with zinc and acetic acid to obtain a product wherein X is H. Protecting groups may subsequently be removed. The following product interconversions are described: (a) dehydrogenation of 4-en-3-ones to 1,4-dien-3-ones; (b) hydrolysis of 3-acyloxy compounds to 3-ols; and (c) conversion of 3,3-ols to 3#-hexosides. 17-(3-Furyl)-steroids of Formula II are prepared (A) by reaction of 3-furyllithium with a 17-oxo-steroid wherein any 3-oxo group is protected (e.g. as enol ether, enamine or ketal) or any 3-hydroxy group is preferably protected (e.g. as tetrahydropyranyl ether), and when the product contains an 11-oxo group, optionally reducing the same to an 11#-hydroxy group preferably while any protecting group in the 3-position is still present; or (B) by reduction with diisobutyl aluminium hydride of card- 20(22)-enolides wherein any 19-aldehyde group is protected (e.g. as ethylene acetal). Further interconversions of compounds of Formula II described are: (a) acylation of a 3-hydroxy group; (b) acylation of a 17#-hydroxy group; and (c) dehydration of a 17α-(3-furyl)-17#-ol, preferably with simultaneous ethylene ketalization of a #<SP>4</SP>-3-oxo group, and hydrogenation of the resulting 17-(3-furyl)-16-ene to obtain a 17#- (3-furyl)-compound, any 11-oxo group present therein then optionally being reduced to 11#- hydroxy, and any 3-ketal group then being hydrolysed. 3,3-Ethylenedioxy-5-androstene-11,17-dione is prepared from 11α,17#-diacetoxy-4-androsten- 3-one via 11α, 17#-diacetoxy-3,3-ethylenedioxy-5- androstene and 3,3-ethylenedioxy-5-androstene- 11α,17#-diol. Similarly there are prepared 3,3-ethylenedioxy-5-estrene-11,17-dione and 3,3- ethylenedioxy-5(10)-estrene-11,17-dione, 3,3-Ethylenedioxy-5-androsten-17-one is prepared from 17#-hydroxy-4-androsten-3-one via 3,3-ethylenedioxy-5-androsten-17#-ol,Similarly there are prepared 3,3-ethylenedioxy-5-estren-17- one, 3,3-ethylenedioxy-5(10)-estren-17-one, and 3,3-ethylenedioxy-5#-androstane-11,17-dione. Steroids of Formula I are stated to possess cardiotonic, antiinflammatory, cholesterol lowering and mineralocorticoid activities and may be made up with acceptable carriers or diluents into pharmaceutical compositions suitable for oral or parenteral administration. Reference has been directed by the Comptroller to Specifications 1,081,647 and 1,145,336.